文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

高危-中危和高危I期子宫内膜癌辅助放疗改善总生存

Improved overall survival with adjuvant radiotherapy for high-intermediate and high risk Stage I endometrial cancer.
PubMed 文献 · Radiother Oncol · 2016-12-21

基于美国国家癌症数据库132,976例FIGO I期子宫内膜样子宫内膜癌手术患者,比较观察与辅助放疗的生存影响。多因素分析显示,高危-中危和高危组辅助放疗显著改善总生存(HR 0.796和0.783),低危和低-中危组无生存获益。

要点

  • 高危-中危I期子宫内膜样癌辅助放疗改善总生存(HR 0.796)。
  • 高危I期子宫内膜样癌辅助放疗改善总生存(HR 0.783)。
  • 低危和低-中危组辅助放疗无生存获益。

核心结论

  • 在I期高危-中危和高危子宫内膜样子宫内膜癌患者中,辅助放疗显著改善总生存。

研究设计与样本

  • 研究纳入美国国家癌症数据库(NCDB)中132,976例接受手术的FIGO I期子宫内膜样子宫内膜癌患者。
  • 患者分为观察组(104,645例,79%)和辅助放疗组(28,331例,21%),放疗方式包括阴道近距离放疗、外照射或两者联合。
  • 采用单变量广义线性混合效应模型估计接受辅助放疗的比值比,多变量脆弱生存模型估计观察与辅助放疗的瞬时死亡风险。
  • 因存在显著交互作用,按PORTEC低危、低-中危、高危-中危和高危风险组分层分析。

主要发现

  • 单因素分析中,分期/肌层浸润增加、分级更高、年龄更大、存在淋巴血管间隙浸润和肿瘤尺寸更大均预测更差生存(所有p<0.01)。
  • 多因素分析显示,高危-中危组接受辅助放疗的患者生存改善,风险比(HR)为0.796(95%CI: 0.731-0.867;p<0.001)。
  • 高危组接受辅助放疗的患者生存改善,HR为0.783(95%CI: 0.693-0.885;p<0.001)。
  • 低危或低-中危组患者接受辅助放疗无生存获益。

关键数值与推荐

  • 高危-中危组辅助放疗对比观察的死亡风险HR为0.796(95%CI: 0.731-0.867;p<0.001)。
  • 高危组辅助放疗对比观察的死亡风险HR为0.783(95%CI: 0.693-0.885;p<0.001)。
  • 低危和低-中危组辅助放疗无生存获益。

临床怎么用

  • 对于I期高危-中危和高危子宫内膜样子宫内膜癌患者,辅助放疗可考虑用于改善总生存。
  • 低危和低-中危患者未显示辅助放疗生存获益,决策时应权衡利弊。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/PURPOSE: To perform a large analysis of Stage I endometrioid-type endometrial cancer patients to determine the impact of adjuvant radiotherapy (ART) on survival. MATERIAL/METHODS: 132,976 FIGO Stage I endometrioid-type endometrial cancer patients treated surgically were identified within the National Cancer Database (NCDB) comprising Commission on Cancer facilities in the United States. Patients were categorized as observation (OBS) or ART (vaginal brachytherapy, external beam radiotherapy, or both). Univariable generalized linear mixed effects models were used to estimate the odds of receiving ART, and a multivariable frailty survival model was used to estimate the instantaneous hazard of death for those receiving OBS versus ART. Due to the presence of a significant interaction, these estimates were stratified by PORTEC-based low, low-intermediate, high-intermediate, and high risk groups. RESULTS: 104,645 (79%) underwent OBS while 28,331 (21%) received ART. Of those receiving ART, 12,913 (46%) received VBT alone, 12,857 (45%) received EBRT alone, and 2561 (9%) received EBRT+VBT. On univariable analysis, increasing stage/myometrial invasion, higher grade, older age, presence of lymphovascular space invasion, and larger tumor size predicted poorer survival (all p<0.01). On multivariable analysis, patients at high-intermediate risk and high risk experienced improved survival with ART with a hazard ratio of 0.796 (95% CI: 0.731-0.867; p<0.001) and 0.783 (95% CI: 0.693-0.885; p<0.001), respectively. There was no survival benefit for ART among patients at low or low-intermediate risk. CONCLUSIONS: In Stage I high-intermediate and high risk endometrioid-type endometrial cancer patients, ART significantly improves overall survival.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Harkenrider MM, Adams W, Block AM, et al. Improved overall survival with adjuvant radiotherapy for high-intermediate and high risk Stage I endometrial cancer. Radiother Oncol. 2016. PMID: 28012794. doi:10.1016/j.radonc.2016.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。